Peiman Hematti

Dr. Peiman Hematti

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Experimental Hematology
Verified
Journal Article
Closed access
JKJaehyup Kim
Jaehyup Kim
PHPeiman Hematti
Peiman Hematti

1 January 2016 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
RDRyan A Denu
Ryan A Denu
PHPeiman Hematti
Peiman Hematti
Mesenchymal stromal/stem cells (MSCs) are multipotent stem cells present in most fetal and adult tissues. Ex vivo culture‐expanded MSCs are being investigated for tissue repair and immune modulation, but their full clinical potential is far from realization. Here we review the role of oxidative stress in MSC biology, as their longevity and functions are affected by oxidative stress. In general, increased reactive oxygen species (ROS) inhibit MSC proliferation, increase senescence, enhance adipogenic but reduce osteogenic differentiation, and inhibit MSC immunomodulation. Furthermore, aging, senescence, and oxidative stress reduce their ex vivo expansion, which is critical for their clinical applications. Modulation of sirtuin expression and activity may represent a method to reduce oxidative stress in MSCs. These findings have important implications in the clinical utility of MSCs for degenerative and immunological based conditions. Further study of oxidative stress in MSCs is imperative in order to enhance MSC ex vivo expansion and in vivo engraftment, function, and longevity.

18 May 2016 in Acta Haematologica
Verified
Journal Article
Open access
PDF file
RDRyan A Denu
Ryan A Denu
SNSteven Nemcek
Steven Nemcek
DBDebra D. Bloom
Debra D. Bloom
AGA. Daisy Goodrich
A. Daisy Goodrich
JKJaehyup Kim
Jaehyup Kim
PHPeiman Hematti
Peiman Hematti
Background/Aims: Human mesenchymal stromal/stem cells (MSCs), derived from many different tissues, are characterized by a fibroblast-like morphology, the expression of certain cell surface markers and their ability to differentiate into adipocytes, chondrocytes and osteoblasts. A number of studies have shown that MSCs share many characteristics with fibroblasts; however, there is no well-defined set of phenotypic characteristics that could distinguish between these 2 types of cells. Methods: We used 4 well-established human fibroblast strains from 3 different tissue sources and several human MSC strains from 2 different tissue sources to compare the phenotypic and immunological characteristics of these cells. Results: Fibroblast strains had a similar morphology to MSCs, expressed the same cell surface markers as MSCs and could also differentiate into adipocytes, chondrocytes and osteoblasts. Also, similar to MSCs, these fibroblasts were capable of suppressing T cell proliferation and modulating the immunophenotype of macrophages. We also show that MSCs deposit extracellular matrices of collagen type I and fibronectin, and express FSP1 in patterns similar to fibroblasts. Conclusions: Based on currently accepted definitions for cultured human MSCs and fibroblasts, we could not find any immunophenotypic property that could make a characteristic distinction between MSCs and fibroblasts.

5 February 2019 in Stem Cells
Verified
Journal Article
Open access
PDF file
CCConnie S. Chamberlain
Connie S. Chamberlain
ACAnna E. B. Clements
Anna E. B. Clements
JKJohn A. Kink
John A. Kink
UCUgeun Choi
Ugeun Choi
GBGeoffrey S. Baer
Geoffrey S. Baer
RVRay Vanderby
Ray Vanderby
Tendon healing follows a complex series of coordinated events that ultimately produces a mechanically inferior tissue more scar‐like than native tendon. More regenerative healing occurs when anti‐inflammatory M2 macrophages play a more dominant role. Mesenchymal stromal/stem cells (MSCs) are able to polarize macrophages to an M2 immunophenotype via paracrine mechanisms. We previously reported that co‐culture of CD14+ macrophages (MQs) with MSCs resulted in a unique M2‐like macrophage. More recently, we generated M2‐like macrophages using only extracellular vesicles (EVs) isolated from MSCs creating “EV‐educated macrophages” (also called exosome‐educated macrophages, EEMs), thereby foregoing direct use of MSCs. For the current study, we hypothesized that cell therapy with EEMs would improve in vivo tendon healing by modulating tissue inflammation and endogenous macrophage immunophenotypes. We evaluated effects of EEMs using a mouse Achilles tendon rupture model and compared results to normal tendon healing (without any biologic intervention), MSCs, MQs, or EVs. We found that exogenous administration of EEMs directly into the wound promoted a healing response that was significantly more functional and more regenerative. Injured tendons treated with exogenous EEMs exhibited 1) improved mechanical properties, 2) reduced inflammation, and 5) earlier angiogenesis. Treatment with MSC‐derived EVs alone were less effective functionally but stimulated a biological response as evidenced by an increased number of endothelial cells and decreased M1/M2 ratio. Because of their regenerative and immunomodulatory effects, EEM treament could provide a novel strategy to promote wound healing in this and various other musculo‐skeletal injuries or pathologies where inflammation and inadequate healing is problematic. Significance Statement Tendon healing results in a mechanically inferior tissue more scar‐like than native tendon. To improve healing outcome, M2‐like macrophages were generated by exposing CD14+ macrophages to extracellular vesicles (EVs), creating “EV‐educated macrophages” (EEMs). EEM treatment to a tendon injury accelerated biological and functional healing. These results have significant clinical relevance in that 1) EEMs are terminally differentiated and will not proliferate or differentiate into undesirable cell types in vivo, 2) EEMs can be generated using off‐the‐shelf EVs, and monocytes collected from a patient's own blood, and 3) the immune‐modulatory effects of EEMs suggest this approach may benefit other inflammatory conditions. © AlphaMed Press 2019

1 March 2008 in Experimental Hematology
Verified
Journal Article
Closed access
PTParul Trivedi
Parul Trivedi
PHPeiman Hematti
Peiman Hematti

1 May 2012 in Cytotherapy
Verified
Journal Article
Closed access
PHPeiman Hematti
Peiman Hematti